Active Ingredient History
Copanlisib, developed by Bayer, is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Copanlisib is currently under Phase II/III clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 1/Phase 2)
BRCA1 Protein (Phase 1)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 1)
Carcinoma, Hepatocellular (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Intestinal Neoplasms (Phase 2)
Kidney Diseases (Phase 1)
Leukemia, B-Cell (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 1)
Medical Oncology (Phase 1)
Mixed Tumor, Malignant (Phase 1/Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neuroblastoma (Phase 1/Phase 2)
Osteosarcoma (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 2)
Postmenopause (Phase 1)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Early Phase 1)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 1/Phase 2)
Sarcoma, Ewing (Phase 1/Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)
Thyroid Cancer, Papillary (Phase 1)
Thyroid Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue